70 related articles for article (PubMed ID: 38745079)
1. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni Syndrome.
Correa H
J Pediatr Genet; 2016 Jun; 5(2):84-8. PubMed ID: 27617148
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts.
Agarwal H; Tal P; Goldfinger N; Chattopadhyay E; Malkin D; Rotter V; Attery A
Cell Death Differ; 2024 May; ():. PubMed ID: 38745079
[TBL] [Abstract][Full Text] [Related]
4. Unaffected Li-Fraumeni Syndrome Carrier Parent Demonstrates Allele-Specific mRNA Stabilization of Wild-Type
Buzby JS; Williams SA; Nugent DJ
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553570
[TBL] [Abstract][Full Text] [Related]
5. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
6. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.
Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V
Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605
[TBL] [Abstract][Full Text] [Related]
7. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene.
Varley JM; Thorncroft M; McGown G; Appleby J; Kelsey AM; Tricker KJ; Evans DG; Birch JM
Oncogene; 1997 Feb; 14(7):865-71. PubMed ID: 9047394
[TBL] [Abstract][Full Text] [Related]
8. Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts.
Burt EC; James LA; Greaves MJ; Birch JM; Boyle JM; Varley JM
Br J Cancer; 2000 Aug; 83(4):467-72. PubMed ID: 10945493
[TBL] [Abstract][Full Text] [Related]
9. Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis.
Light N; Layeghifard M; Attery A; Subasri V; Zatzman M; Anderson ND; Hatkar R; Blay S; Chen D; Novokmet A; Fuligni F; Tran J; de Borja R; Agarwal H; Waldman L; Abegglen LM; Albertson D; Finlay JL; Hansford JR; Behjati S; Villani A; Gerstung M; Alexandrov LB; Somers GR; Schiffman JD; Rotter V; Malkin D; Shlien A
Nat Commun; 2023 Jan; 14(1):77. PubMed ID: 36604421
[TBL] [Abstract][Full Text] [Related]
10. Targeting mitochondrial metabolism for precision medicine in cancer.
Sainero-Alcolado L; Liaño-Pons J; Ruiz-Pérez MV; Arsenian-Henriksson M
Cell Death Differ; 2022 Jul; 29(7):1304-1317. PubMed ID: 35831624
[TBL] [Abstract][Full Text] [Related]
11. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas.
Curylova L; Ramos H; Saraiva L; Skoda J
Cancer Lett; 2022 Jan; 525():131-145. PubMed ID: 34742870
[TBL] [Abstract][Full Text] [Related]
12. eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer.
Chen YX; Wang CJ; Xiao DS; He BM; Li M; Yi XP; Zhang W; Yin JY; Liu ZQ
Pharmacol Res; 2021 Dec; 174():105934. PubMed ID: 34648968
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype.
Kumari R; Jat P
Front Cell Dev Biol; 2021; 9():645593. PubMed ID: 33855023
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy.
Lonetto G; Koifman G; Silberman A; Attery A; Solomon H; Levin-Zaidman S; Goldfinger N; Porat Z; Erez A; Rotter V
Cell Death Differ; 2019 Sep; 26(9):1566-1581. PubMed ID: 30413783
[TBL] [Abstract][Full Text] [Related]
15. DNA repair processes are critical mediators of p53-dependent tumor suppression.
Janic A; Valente LJ; Wakefield MJ; Di Stefano L; Milla L; Wilcox S; Yang H; Tai L; Vandenberg CJ; Kueh AJ; Mizutani S; Brennan MS; Schenk RL; Lindqvist LM; Papenfuss AT; O'Connor L; Strasser A; Herold MJ
Nat Med; 2018 Jul; 24(7):947-953. PubMed ID: 29892060
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
